Reclassifying contralateral axillary metastasis: survival benefit of aggressive local therapy challenges stage IV designation

对侧腋窝转移瘤重新分类:积极局部治疗的生存获益挑战了IV期分期标准

阅读:1

Abstract

BACKGROUND: Contralateral axillary metastasis (CAM) is currently staged as M1 (stage IV) breast cancer, guiding treatment towards palliative systemic therapy. However, emerging evidence suggests CAM may behave as a locoregional event, potentially amenable to curative-intent strategies. This study aims to define the prognosis of isolated CAM and evaluate the survival impact of aggressive local therapy. METHODS: We conducted a retrospective cohort study of 1110 patients from two tertiary centers, comprising three cohorts: CAM (n=128), stage IIIC locally advanced breast cancer (LABC, n=532), and de novo oligometastatic (M1, n=450) disease. Overall survival (OS) was compared using Kaplan-Meier and multivariable Cox regression. Within the CAM cohort, we employed propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and multivariable Cox models to compare outcomes between patients receiving curative-intent local therapy (surgery/radiotherapy) versus a systemic therapy-focused approach. RESULTS: The adjusted mortality risk for the CAM cohort was significantly lower than for the M1 cohort (aHR 0.58, 95% CI 0.45–0.74) but higher than for the LABC cohort (aHR 1.18, 95% CI 0.93–1.60). In the PSM analysis, curative-intent therapy was associated with a 51% reduction in mortality risk (HR 0.49, 95% CI 0.31–0.78) and a significantly lower 5-year cumulative incidence of locoregional recurrence (12.1% vs. 31.4%, p=0.005). Results were consistent across IPTW and multivariable analyses. CONCLUSION: Patients with isolated CAM exhibit a prognosis distinct from classic stage IV disease. A curative-intent local treatment strategy is independently associated with significantly improved survival and locoregional control, supporting the re-evaluation of CAM as a clinically regionally treatable entity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。